Table 2.

IBAT inhibitors in development.[40], [41], [42], [43], [44], [45], [46], [47], [48], [49], [50], [51], [52]

IBAT inhibitor	Approved indication	Target indication(s)
Odevixibat	PFIC (EU and US)40 Alagille syndrome (US)41	Biliary atresia42
Maralixibat	Alagille syndrome (EU and US)43	PFIC44 Biliary atresia45
Elobixibat	Chronic constipation (Japan)46	Non-alcoholic steatohepatitis47 Non-alcoholic fatty liver disease47
Linerixibat	n.a.	Type 2 diabetes48 Cholestasis49 Primary biliary cholangitis50
Volixibat	n.a.	Non-alcoholic steatohepatitis51 Primary sclerosing cholangitis52

IBAT, ileal bile acid transporter; PFIC, progressive familial intrahepatic cholestasis; n.a., not applicable.